Boston Scientific reported robust Q4 and full-year 2025 results, with organic sales growth reaching the high end of guidance. The company provided a confident outlook for 2026, driven by strength in its Electrophysiology and WATCHMAN franchises, while addressing near-term headwinds in other segments.
Boston Scientific met Q4 revenue expectations and delivered a slight earnings beat, but a sharp stock decline reflects investor scrutiny over sequential softness in key franchises and margin pressures.
Medical device giant Boston Scientific (BSX) is scheduled to release its fourth-quarter financial results before market open on Wednesday, with Wall Street anticipating continued strong revenue growth and another potential earnings beat.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
